The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
The poster reports the patient reported outcomes from the SAPHYR study. Patients treated with sarilumab 200mg Q2W + 14-week GC had clinically meaningful and robust improvement in patient reported outcomes compared to patients receiving placebo + 52-week GC.